Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Seres Therapeutics (Nasdaq: MCRB) said it will host a webcast on July 8, 2026 (8:30 a.m. ET) to discuss top-line results from an investigator-sponsored trial at Memorial Sloan Kettering of SER-155 in immune checkpoint inhibitor-related enterocolitis. The open-label study enrolled 15 patients with Grade 2–3 irEC; the primary endpoint is an immunosuppressive-free clinical response on Day 15.
How this was made
The 30-second read
Why it matters
The announcement creates a near-term information event (webcast) tied to top-line results from NCT06801067, which could re-rate SER-155’s clinical promise in irEC and influence expectations for the broader live biotherapeutics platform.
Market read
Traders get a concrete upcoming catalyst date for MCRB tied to irEC top-line readouts, but the release contains no efficacy/safety numbers.
What to watch
Key decision points are whether Day 15 immunosuppressive-free clinical response is achieved and whether safety/tolerability is compelling; the article does not address these outcomes.
Background
Seres’ SER-155 is being studied for immune checkpoint inhibitor-related enterocolitis (irEC), a common and serious adverse event where standard care typically involves halting ICI therapy and using corticosteroids.
Ticker impact
Seres announced a July 8 webcast on top-line results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis.
Moderate, event-driven volatility into the July 8 webcast; direction depends on whether top-line results support an immunosuppressive-free response.
The article discloses a new, time-specific catalyst (webcast date) and trial design/endpoint, but provides no actual results or numbers yet.
Market effects
Highlights ongoing interest in microbiome/live biotherapeutics as potential alternatives to corticosteroids for immune-mediated GI toxicities.
No specific regional market linkage beyond US oncology/biotech investor attention.
Immune checkpoint inhibitor adverse-event management is globally relevant, but the disclosed event is company-specific.
Counterpoint
Because this is an investigator-sponsored, open-label trial with only 15 participants and no results provided, the market may discount the impact until formal data are published.
Key entities
- companySeres Therapeutics, Inc.
Nasdaq-listed live biotherapeutics company hosting a webcast to discuss SER-155 irEC investigator-sponsored trial top-line results.
- drug_candidateSER-155
Live biotherapeutic evaluated in an investigator-sponsored trial for immune checkpoint inhibitor-related enterocolitis.
- clinical_trialNCT06801067
Investigator-sponsored, open-label trial evaluating SER-155 in Grade 2-3 irEC patients.
- research_siteMemorial Sloan Kettering Cancer Center
Trial site with principal investigator David Faleck, M.D.
